Cell Death Discovery,
Journal Year:
2023,
Volume and Issue:
9(1)
Published: Feb. 7, 2023
Abstract
Although
dysregulated
HMMR
is
linked
to
prostate
cancer
(PCa)
prognosis,
the
precise
mechanisms
remain
unclear.
Here,
we
sought
elucidate
role
of
in
PCa
progression
as
well
underlying
mechanism.
Herein,
found
that
upregulation
frequently
observed
samples
and
was
associated
with
poor
prognosis.
Additionally,
significantly
promoted
proliferation
metastasis
through
gain-
loss-of
function
approaches
vitro
vivo.
Mechanistically,
may
interact
AURKA
elevated
protein
level
inhibiting
ubiquitination-mediated
degradation,
which
subsequently
activated
mTORC2/AKT
pathway
ensure
reinforcement
progression.
Moreover,
upregulated
E2F1
caused
from
sustained
activation
turn
transcription
factor
promote
transcription,
thereby
forming
a
positive
feedback
loop
trigger
Importantly,
administration
mTOR
inhibitor
partially
antagonised
HMMR-mediated
In
summary,
not
only
reveal
novel
possible
post-translation
mechanism
mediated
by
involved
regulation,
but
also
describe
contributes
deterioration,
suggesting
serve
potential
promising
therapeutic
target
PCa.
Signal Transduction and Targeted Therapy,
Journal Year:
2023,
Volume and Issue:
8(1)
Published: March 11, 2023
Abstract
Despite
the
success
of
targeted
therapies
in
cancer
treatment,
therapy-induced
resistance
remains
a
major
obstacle
to
complete
cure.
Tumor
cells
evade
treatments
and
relapse
via
phenotypic
switching
driven
by
intrinsic
or
induced
cell
plasticity.
Several
reversible
mechanisms
have
been
proposed
circumvent
tumor
plasticity,
including
epigenetic
modifications,
regulation
transcription
factors,
activation
suppression
key
signaling
pathways,
as
well
modification
environment.
Epithelial-to-mesenchymal
transition,
stem
formation
also
serve
roads
towards
Corresponding
treatment
strategies
recently
developed
that
either
target
plasticity-related
employ
combination
treatments.
In
this
review,
we
delineate
plasticity
its
manipulation
evasion
from
therapy.
We
discuss
non-genetic
drug-induced
various
types
tumors
provide
insights
into
contribution
acquired
drug
resistance.
New
therapeutic
such
inhibition
reversal
are
presented.
multitude
clinical
trials
ongoing
worldwide
with
intention
improving
outcomes.
These
advances
direction
for
developing
novel
therapy
regimens
Cancers,
Journal Year:
2023,
Volume and Issue:
15(5), P. 1412 - 1412
Published: Feb. 23, 2023
Over
the
past
decade,
immunotherapy
has
demonstrated
an
impressive
improvement
in
treatment
outcomes
for
multiple
cancers.
Following
landmark
approvals
use
of
immune
checkpoint
inhibitors,
new
challenges
emerged
various
clinical
settings.
Not
all
tumor
types
harbor
immunogenic
characteristics
capable
triggering
responses.
Similarly,
many
tumors’
microenvironment
allows
them
to
become
evasive,
leading
resistance
and,
thus,
limiting
durability
To
overcome
this
limitation,
T-cell
redirecting
strategies
such
as
bispecific
engager
(BiTE)
have
attractive
and
promising
immunotherapies.
Our
review
provides
a
comprehensive
perspective
current
evidence
BiTE
therapies
solid
tumors.
Considering
that
shown
modest
results
advanced
prostate
cancer
date,
we
biologic
rationale
therapy
setting
discuss
potential
tumor-associated
antigens
may
be
integrated
into
construct
designs.
also
aims
evaluate
advances
cancer,
illustrate
major
obstacles
underlying
limitations,
directions
future
research.
Cancers,
Journal Year:
2025,
Volume and Issue:
17(2), P. 194 - 194
Published: Jan. 9, 2025
Prostate
cancer
is
one
of
the
most
common
diseases
among
men
worldwide
and
continues
to
pose
a
serious
threat
health.
This
review
shows
history
new
developments
in
management
prostate
cancer,
with
an
emphasis
on
range
therapeutic
approaches,
such
as
hormone
therapy,
radiation
surgery,
innovative
targeted
therapeutics.
The
evolution
these
treatments
examined
light
clinical
outcomes,
patient
quality
life,
emerging
resistance
mechanisms,
recently
shown
vitamin
D-based
strategies.
New
that
have
potential
increase
survival
rates
reduce
side
effects
are
also
discussed,
including
PARP
inhibitors
(PARPis),
immunotherapy,
tailored
medication.
Additionally,
use
biomarkers
sophisticated
imaging
methods
decision-making
explored,
focus
how
tools
might
improve
care.
absolute
necessity
for
multidisciplinary
approach
improving
treatment
strategies
becoming
more
apparent
our
understanding
biology
deepens.
ensures
patients
receive
customized
medicines
fit
their
unique
profiles.
Future
avenues
investigation
will
resolving
issues
dealing
efficacy
results,
ultimately
leading
disease
cure
patients.
